Respiratory and sleep breathing player ResMed ($RMD) said a study showed positive results for its portable oxygen therapy, remote monitoring technology and home non-invasive ventilation (NIV) system designed for COPD patients.
In addition to the study results, the San Diego-based device maker unveiled its LifeChoice Activox 4LTM portable oxygen concentrator developed by Inova Labs, which ResMed acquired earlier this year for an undisclosed price.
According to the Home Oxygen Therapy- Home Mechanical Ventilation study, adding home NIV to home oxygen therapy improves admission-free survival of COPD patients with high levels of carbon dioxide in the blood following a life-threatening increase of COPD requiring acute NIV, the company said.
The study also showed an increase in patients’ median (hospital) admission-free survival from 1.4 months in the group receiving home oxygen therapy only, to 4.3 months in the group receiving the home therapy along with home NIV.
“These results build on and add further weight to existing evidence supporting the broader use of home NIV in patients living with COPD, whilst also underlining the accepted benefits of home NIV in terms of reducing hospital admissions and improving patient outcomes,” Holger Woehrle, vice president of clinical research, said in a statement.
In debuting its newest product, ResMed said the portable oxygen concentrator features a “class-leading battery autonomy” and is less intrusive than traditional oxygen delivery formats. The device frees COPD patients who are still mobile from bulkier and heavier options like tanks and liquid oxygen. The LifeChoice Activox provides smoother oxygen delivery.
- here’s the release
ResMed rolls out CPAP treatment tracker app
ResMed sues Chinese medical device maker for patent infringement in the U.S.
Monitoring improves sleep apnea device compliance: Kaiser study